Univariate and multivariate analyses of factors influencing NRM among patients transplanted in CR1, according to donor type
| Covariates . | Related (n = 310) . | Unrelated (n = 331) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | Univariate . | Multivariate . | N . | Univariate . | Multivariate . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| WBC count at diagnosis | ||||||||||
| < 30 000/μL | 224 | 1.00 | — | 230 | 1.00 | — | ||||
| 30 000/μL or more at diagnosis | 86 | 1.21 (0.63-2.34) | .57 | — | 101 | 0.79 (0.48-1.30) | .35 | — | ||
| Lineage | ||||||||||
| B | 218 | 1.00 | — | 203 | 1.00 | — | ||||
| T | 50 | 1.25 (0.41-3.81) | .53 | — | 54 | 0.62 (0.29-1.38) | .17 | — | ||
| Other | 42 | 0.87 (0.34-2.26) | .78 | — | 74 | 1.08 (0.65-1.81) | .76 | — | ||
| Karyotype | ||||||||||
| Normal | 193 | 1.00 | — | 208 | 1.00 | — | ||||
| t(4;11) or t(1;19) | 21 | 0.77 (0.16-3.17) | .73 | — | 11 | 1.03 (0.25-4.30) | .63 | 1.11 (0.27-4.64) | .57 | |
| Other (no t(9;22)) | 96 | 0.92 (0.47-1.81) | .81 | — | 112 | 1.47 (0.94-2.29) | .09 | 1.67 (1.06-2.64) | .03 | |
| JALSG risk stratification | ||||||||||
| Low | 39 | 1.00 | — | 45 | 1.00 | — | ||||
| Intermediate | 163 | 1.85 (0.86-3.97) | .12 | — | 192 | 1.01 (0.62-1.65) | .96 | — | ||
| High | 108 | 2.82 (1.09-7.31) | .03 | — | 94 | 1.03 (0.50-2.10) | .94 | — | ||
| Age at allo-SCT | ||||||||||
| < 45 y old | 255 | 1.00 | — | 281 | 1.00 | — | ||||
| 45 y old or older at allo-SCT | 55 | 3.90 (2.09-7.25) | < .0001 | 3.90 (2.09-7.25) | < .0001 | 50 | 1.26 (0.72-2.20) | .42 | ||
| HLA | ||||||||||
| Match | 285 | 1.00 | — | 192 | 1.00 | — | ||||
| Mismatch | 25 | 1.64 (0.64-4.18) | .30 | — | 139 | 1.69 (1.10-2.60) | .02 | 1.69 (1.10-2.61) | .02 | |
| Stem cell source | ||||||||||
| Bone marrow | 212 | 1.00 | — | — | ||||||
| Peripheral blood | 98 | 1.75 (0.94-3.28) | .08 | — | — | |||||
| Time from diagnosis to allo-SCT | ||||||||||
| 6 mo or longer | 169 | 1.00 | — | 23 | 1.00 | — | ||||
| < 6 mo | 141 | 1.64 (0.87-3.11) | .13 | — | 308 | 0.31 (0.08-1.25) | .10 | — | ||
| < 10 mo | 278 | 1.00 | — | 166 | 1.00 | — | ||||
| 10 mo or longer | 32 | 1.07 (0.42-2.72) | .89 | — | 165 | 1.90 (1.21-2.99) | .01 | 1.98 (1.26-3.13) | .003 | |
| Preparative regimen | ||||||||||
| Non-TBI regimens | 25 | 1.00 | — | 12 | 1.00 | — | ||||
| TBI regimens | 285 | 0.63 (0.25-1.61) | .34 | — | 319 | 0.67 (0.25-1.85) | .44 | — | ||
| GVHD prophylaxis | ||||||||||
| Cyclosporine A with or without other | 283 | 1.00 | — | 171 | 1.00 | — | ||||
| Tacrolimus with or without other | 27 | 1.66 (0.65-3.80) | .29 | — | 160 | 1.33 (0.86-2.05) | .52 | — | ||
| Covariates . | Related (n = 310) . | Unrelated (n = 331) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | Univariate . | Multivariate . | N . | Univariate . | Multivariate . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| WBC count at diagnosis | ||||||||||
| < 30 000/μL | 224 | 1.00 | — | 230 | 1.00 | — | ||||
| 30 000/μL or more at diagnosis | 86 | 1.21 (0.63-2.34) | .57 | — | 101 | 0.79 (0.48-1.30) | .35 | — | ||
| Lineage | ||||||||||
| B | 218 | 1.00 | — | 203 | 1.00 | — | ||||
| T | 50 | 1.25 (0.41-3.81) | .53 | — | 54 | 0.62 (0.29-1.38) | .17 | — | ||
| Other | 42 | 0.87 (0.34-2.26) | .78 | — | 74 | 1.08 (0.65-1.81) | .76 | — | ||
| Karyotype | ||||||||||
| Normal | 193 | 1.00 | — | 208 | 1.00 | — | ||||
| t(4;11) or t(1;19) | 21 | 0.77 (0.16-3.17) | .73 | — | 11 | 1.03 (0.25-4.30) | .63 | 1.11 (0.27-4.64) | .57 | |
| Other (no t(9;22)) | 96 | 0.92 (0.47-1.81) | .81 | — | 112 | 1.47 (0.94-2.29) | .09 | 1.67 (1.06-2.64) | .03 | |
| JALSG risk stratification | ||||||||||
| Low | 39 | 1.00 | — | 45 | 1.00 | — | ||||
| Intermediate | 163 | 1.85 (0.86-3.97) | .12 | — | 192 | 1.01 (0.62-1.65) | .96 | — | ||
| High | 108 | 2.82 (1.09-7.31) | .03 | — | 94 | 1.03 (0.50-2.10) | .94 | — | ||
| Age at allo-SCT | ||||||||||
| < 45 y old | 255 | 1.00 | — | 281 | 1.00 | — | ||||
| 45 y old or older at allo-SCT | 55 | 3.90 (2.09-7.25) | < .0001 | 3.90 (2.09-7.25) | < .0001 | 50 | 1.26 (0.72-2.20) | .42 | ||
| HLA | ||||||||||
| Match | 285 | 1.00 | — | 192 | 1.00 | — | ||||
| Mismatch | 25 | 1.64 (0.64-4.18) | .30 | — | 139 | 1.69 (1.10-2.60) | .02 | 1.69 (1.10-2.61) | .02 | |
| Stem cell source | ||||||||||
| Bone marrow | 212 | 1.00 | — | — | ||||||
| Peripheral blood | 98 | 1.75 (0.94-3.28) | .08 | — | — | |||||
| Time from diagnosis to allo-SCT | ||||||||||
| 6 mo or longer | 169 | 1.00 | — | 23 | 1.00 | — | ||||
| < 6 mo | 141 | 1.64 (0.87-3.11) | .13 | — | 308 | 0.31 (0.08-1.25) | .10 | — | ||
| < 10 mo | 278 | 1.00 | — | 166 | 1.00 | — | ||||
| 10 mo or longer | 32 | 1.07 (0.42-2.72) | .89 | — | 165 | 1.90 (1.21-2.99) | .01 | 1.98 (1.26-3.13) | .003 | |
| Preparative regimen | ||||||||||
| Non-TBI regimens | 25 | 1.00 | — | 12 | 1.00 | — | ||||
| TBI regimens | 285 | 0.63 (0.25-1.61) | .34 | — | 319 | 0.67 (0.25-1.85) | .44 | — | ||
| GVHD prophylaxis | ||||||||||
| Cyclosporine A with or without other | 283 | 1.00 | — | 171 | 1.00 | — | ||||
| Tacrolimus with or without other | 27 | 1.66 (0.65-3.80) | .29 | — | 160 | 1.33 (0.86-2.05) | .52 | — | ||
HR indicates hazard ratio; CI, confidence interval; WBC, white blood cell; —, not applicable; and TBI, total body irradiation.